Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study - Report - MDSpire
Advertisement
Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study
Clinical Report: Safety and Effectiveness of Neoadjuvant Camrelizumab and Apatinib
Overview
This phase II study evaluates the safety and efficacy of neoadjuvant camrelizumab and apatinib combined with chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC). Results indicate that this combination therapy is feasible and may enhance surgical outcomes, with 64.5% of patients proceeding to surgery.
Background
Stage IIIA (N2) non-small cell lung cancer (NSCLC) presents significant treatment challenges, with high recurrence rates post-surgery. Neoadjuvant therapies, including immunotherapy and chemotherapy, are being explored to improve surgical outcomes and reduce micrometastatic disease. The integration of camrelizumab and apatinib with chemotherapy aims to leverage their synergistic effects to enhance treatment efficacy.
Data Highlights
No numerical data provided in the source material.
Key Findings
64.5% of patients in the study proceeded to surgical intervention after neoadjuvant therapy.
Camrelizumab, a PD-1 inhibitor, combined with apatinib and chemotherapy showed an acceptable safety profile.
The study was conducted across four centers in China, enrolling patients aged 18 to 75 with resectable stage IIIA (N2) NSCLC.
Patients received 2-4 cycles of neoadjuvant therapy before surgery.
Preclinical studies support the combination of immunotherapy and chemotherapy for enhanced anti-cancer effects.
Clinical Implications
The findings suggest that neoadjuvant therapy with camrelizumab and apatinib may be a viable option for patients with stage IIIA (N2) NSCLC, potentially improving surgical outcomes. Clinicians should consider this combination in the context of a multimodal treatment strategy for locally advanced NSCLC.
Conclusion
Neoadjuvant camrelizumab and apatinib combined with chemotherapy appears to be a promising approach for patients with resectable stage IIIA (N2) NSCLC, warranting further investigation in larger trials.
